The All Wales Medicines Strategy Group (AWMSG) advises Welsh Government about the use, management and prescribing of medicines in Wales. AWTTC supports AWMSG and its subgroups. The role of AWMSG is to:
Download the AWMSG Constitution
AWTTC supports AWMSG and its subgroups: the New Medicines Group (NMG) and the All Wales Prescribing Advisory Group (AWPAG). AWTTC’s staff work on health technology assessments; managing medicines prescribing, safety and toxicology; and analysing prescribing data which is then considered by AWMSG and its subgroups.
This document sets out a five-year strategy for AWMSG, aligned with Welsh Government’s Prudent Healthcare initiative, and the principles outlined in Taking Wales Forward and Prosperity for All: the national strategy.
Download the AWMSG Five Year Strategy 2018-2023
Previous versions of the AWMSG strategy are available from the Medicines Strategy for Wales page.
The committee is made up of NHS consultants, GPs, nurses, pharmacists, health economists, pharmaceutical industry representatives and lay members who combine their expertise and knowledge to agree on the use of medicines in primary and secondary care in Wales.
AWMSG usually meets 10 times a year and meetings are open to the public. The dates and meeting papers for future AWMSG meetings plus minutes and agendas of past meetings are available from the AWMSG meetings page.
All AWMSG members have to complete a Declaration of Interest form every year and before taking part in any AWMSG meeting.
AWMSG voting members are:
|Prof Iolo Doull||Chair|
|Prof Stephen Monaghan||Consultant in Public Health Medicine|
|Eleri Shiavone||Welsh Health Specialised Services Committee|
|Prof Dyfrig Hughes||Health Economist|
|Farhan Mughal / Tommy Price / Kate Parrish||ABPI Wales representative (one representative present per meeting)|
|Cliff Jones||Lay Representative|
|Claire James||Lay Representative|
|Dylan Jones||Community Pharmacist|
|Dr Jim McGuigan||Medical Director|
|Dr Jeremy Black||GP with prescribing lead role|
|Alison Hughes||Managed Sector Pharmacist|
|John Terry||Managed Sector Pharmacist|
|Hywel Pullen||Director of Finance|
|Mandy James||Senior Nurse|
|Cathy Wynne||Other healthcare professionals eligible to prescribe|
|Dr Alison Thomas||Clinical Pharmacologist|
|Dr Samantha Cox||Hospital Consultant|
|Our deputy voting members are:|
|Vacant||Consultant in Public Health Medicine|
|Dr Helen Fardy||Welsh Health Specialised Services Committee|
|Prof Pippa Anderson||Health Economist|
|Vacant||GP with prescribing lead role|
|Rafia Jamil||Managed Sector Pharmacist|
|Stuart Rees||Managed Sector Pharmacist|
|James Leaves||Director of Finance|
|Katherine White||Senior Nurse|
|Karl Jackson||Other healthcare professions eligible to prescribe|
|Dr Manjeet Singh||Clinical Pharmacologist|
|Dr Manjeet Singh||Hospital Consultant|
Representatives from Welsh Government, the New Medicines Group (NMG) and the All Wales Therapeutics and Toxicology Centre (AWTTC) also come to our meetings but are non-voting.
Download the latest AWMSG Annual Report 2020-2021
Previous AWMSG annual reports are available from the AWMSG annual reports page.
In late 1999, Welsh Government’s Health and Social Services Minister set up a Task & Finish Group for Prescribing, chaired by Sir Norman Mills, to advise on improving prescribing practices and the provision of medicines in Wales. The Task & Finish Group recommended setting up an All-Wales Medicines Strategy Group and developing an All-Wales Prescribing Strategy. The All Wales Medicines Strategy Group (AWMSG) was established in 2002 to advise Welsh Government on medicines management and prescribing in an effective, efficient and transparent manner.
Download the report of the Task and Finish Group for Prescribing, published in 2001.
The New Medicines Group (NMG) is a sub-group of AWMSG and supports the assessments of new medicines. NMG members consider all the evidence about how well a medicine works and how much it will cost NHS Wales (clinical effectiveness and cost-effectiveness). This includes all the information submitted by a pharmaceutical company, healthcare professionals and patients, carers and patient organisations or support groups.
NMG meets up to 10 times a year, to talk about all the evidence for each medicine being assessed. At the meeting they will agree on a recommendation to give to AWMSG about each medicine. Dates of NMG meetings for 2021 are available from the NMG meetings page.
All NMG meetings are held in private.
All NMG members have to fill in a Declaration of Interest form every year and before taking part in any NMG meeting.
The All Wales Prescribing Advisory Group (AWPAG) is a sub-group of AWMSG and advises on strategic developments in the prescribing of medicines and their safe and effective use in Wales.
AWPAG works to:
AWPAG meetings are held in private. Dates of AWPAG meetings for 2021 and minutes from previous meetings are available from the AWPAG meetings page.
All AWPAG members have to complete a Declaration of Interest form every year and before taking part in any AWPAG meeting.
The Steering Committee plans and prioritises the AWMSG work programme.
The committee is made up of:
The committee meets every month, in private, to:
To talk about the medicines appraisals programme, representatives of the following may be invited:
OWMAG was formerly known as the Interim Pathways Commissioning Group (IPCG) until June 2021. OWMAG comprises representation from all IPFR panels, a lay member, industry representative, finance representative, a clinical pharmacologist and a health economist. You can download information about OWMAG membership.
Minutes from previous meetings are available from the OWMAG meetings page.
The IPFR Quality Assurance Advisory Group meets every three months to review a sample of individual patient funding requests made across Wales. It ensures that each health board and the Welsh Health Specialised Services Committee have followed the correct processes. They advise panels on any areas that need improvement and share examples of good practice across the panels.
Minutes from previous meetings and Terms of Reference are available from the IPFR Quality Assurance Advisory Group page.